TrialHaematologica2015

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.

Maximilian Merz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.